Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00185
|
|||||
| Drug Name |
Pazopanib hydrochloride
|
|||||
| Synonyms |
5-((4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide; 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide; 5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide; 790713-33-6; 7RN5DR86CK; DSSTox_CID_28659; DSSTox_GSID_48733; DSSTox_RID_82929; GW 78603; GW 786034; GW-786034; GW786034; MFCD11616589; NCGC00188865-01; Pazopanib; Pazopanib (GW-786034); UNII-7RN5DR86CK; Votrient (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Renal cell carcinoma [ICD11: 2C90] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H24ClN7O2S
|
|||||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
|
|||||
| InChI |
InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
|
|||||
| InChIKey |
MQHIQUBXFFAOMK-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 444731-52-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 474 | Topological Polar Surface Area | 127 | ||
| Heavy Atom Count | 32 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 8 | |||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:71217
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
| References | ||||||
| 1 | Pazopanib hydrochloride was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. | |||||
| 3 | Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.